ALFA Finder| Revenue growth | FY26 consolidated revenue reached ₹142cr; 10% domestic growth. |
|---|---|
| Margins | Consolidated EBITDA at 40%; Co-Res margins currently lower. |
| Demand visibility | Strong demand in oncology and AMR; seasonal flu impacts domestic. |
| Management confidence | Confident in international expansion; optimistic about US FDA outcomes. |
Growth
Consolidated growth supported by Co-Res and TruPCR Europe; domestic growth slowed to 7-10% due to base effects and competition.
Outlook
Management guides for 15-20% consolidated revenue and EBITDA growth for FY27, targeting US FDA clearance for AMR products.
Risks
Intense Chinese competition in respiratory products and high employee costs in Belgium (Co-Res) impacting consolidated EBITDA margins.
Earnings Call filed with BSE, NSE: 3BBLACKBIO. Summary written with AI assistance from the document.
3B BlackBio Dx Ltd: key numbers
- Share price
- ₹1,332.80
- Market cap
- ₹1,144 Cr
- Revenue (annual)
- ₹141.9 Cr
- Net profit (annual)
- ₹59.93 Cr
- P/E (TTM)
- 20.6×Sector 35.5×
- Promoter holding
- 40.95%+0.00% QoQ
- FII holding
- 2.46%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from 3B BlackBio Dx Ltd
All →3B BlackBio Dx Board Meeting Date
3B BlackBio Dx Ltd has scheduled a board meeting for November 13, 2026. The board will consider unaudited standalone and consolidated financial results for the quarter ended September 30, 2026.
3B BlackBio Dx Other Announcement
The company submitted its quarterly shareholding pattern as per Regulation 31(1)(b) of the SEBI Listing Regulations for the period ending September 30, 2026.
3B BlackBio Dx Other Announcement
3B BlackBio DX Limited announced the re-appointment of Mrs. Mithla Dubey as a Non-Executive Non-Independent Director. Her re-appointment follows retirement by rotation.
3B BlackBio Dx Annual General Meeting
3B BlackBio Dx Ltd shareholders approved a dividend of Rs. 5.00 per share at its 54th AGM. The company also presented an investor overview of its FY26 performance.
3B BlackBio Dx Other Announcement
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Annual Report
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.